Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6054-6062

  Zhang, Baolin ^a,c   Zhang, Yaqin ^a   Dagher, Marie Claire ^b   Shacter, Emily ^a  

^a Center for Drug Evaluation and Research   (United States)

^b CNRS   (France)

^c Building 29A ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DOXORUBICIN; ETOPOSIDE; GUANOSINE TRIPHOSPHATASE; INHIBITOR PROTEIN; PROTEIN CDC42; RAC1 PROTEIN; RHO GDP DISSOCIATION INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; STAUROSPORINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROTECTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CASPASE 3; CASPASES; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; LYMPHOMA; MOLECULAR SEQUENCE DATA; MUTATION; RAC1 GTP-BINDING PROTEIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 22244467726     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0175     Document Type: Article

References (35)

1. Olofsson B. Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal 1999;11:545-54.
2. Sasaki T, Takai Y. The Rho small G protein family-Rho GDI system as a temporal and spatial determinant for cytoskeletal control. Biochem Biophys Res Commun 1998;245:641-5.
3. Adra CN, Manor D, Ko JL, et al. RhoGDIγ: a GDP-dissociation inhibitor for Rho proteins with preferential expression in brain and pancreas. Proc Natl Acad Sci U S A 1997;94:4279-84.
4. Golovanov AP, Chuang TH, DerMardirossian C, et al. Structure-activity relationships in flexible protein domains: regulation of rho GTPases by RhoGDI and D4 GDI. J Mol Biol 2001;305:121-35.
5. Fukumoto Y, Kaibuchi K, Hori Y, et al. Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like small GTP-binding proteins. Oncogene 1990;5:1321-8.
6. Takaishi K, Kikuchi A, Kuroda S, Kotani K, Sasaki T, Takai Y. Involvement of rho p21 and its inhibitory GDP/ GTP exchange protein (rho GDI) in cell motility. Mol Cell Biol 1993;13:72-9.
7. Miura Y, Kikuchi A, Musha T, et al. Regulation of morphology by rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI) in Swiss 3T3 cells. J Biol Chem 1993;268:510-5.
8. 2+-dependent exocytosis from PC12 cells. Genes Cells 1996;1:943-51.
9. Togawa A, Miyoshi J, Ishizaki H, et al. Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIα. Oncogene 1999;18:5373-80.
10. Wei L, Imanaka-Yoshida K, Wang L, et al. Inhibition of Rho family GTPases by Rho GDP dissociation inhibitor disrupts cardiac morphogenesis and inhibits cardiomyocyte proliferation. Development 2002;129:1705-14.
11. Rivero F, Illenberger D, Somesh BP, Dislich H, Adam N, Meyer AK. Defects in cytokinesis, actin reorganization and the contractile vacuole in cells deficient in RhoGDI. EMBO J 2002;21:4539-49.
12. Jones MB, Krutzsch H, Shu H, et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002;2:76-84.
13. Hondermarck H, Vercoutter-Edouart AS, Revillion F, et al. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 2001;1:1216-32.
14. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 2002;87:635-44.
15. Fritz G, Just I, Kaina B. Rho GTPases are overexpressed in human tumors. Int J Cancer 1999;81:682-7.
16. Poland J, Schadendorf D, Lage H, Schnolzer M, Celis JE, Sinha P. Study of therapy resistance in cancer cells with functional proteome analysis. Clin Chem Lab Med 2002;40:221-34.
17. Sinha P, Kohl S, Fischer J, et al. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 2000;21:3048-57.
18. Takano M, Goto T, Sakamoto M, et al. Identification of paclitaxel-resistance related genes by differential display using cDNA microarray in ovarian cancer cell lines. Proc Am Soc Clin Oncol 2003;22:462.
19. Zhang B, Zhang Y, Shacter E. Caspase 3-mediated inactivation of rac GTPases promotes drug-induced apoptosis in human lymphoma cells. Mol Cell Biol 2003;23:5716-25.
20. Zhang B, Zhang Y, Shacter E. Rac1 inhibits apoptosis in human lymphoma cells by stimulating Bad phosphorylation on Ser-75. Mol Cell Biol 2004;24:6205-14.
21. Grizot S, Faure J, Fieschi F, Vignais PV, Dagher MC, Pebay-Peyroula E. Crystal structure of the Rac1-RhoGDI complex involved in NADPH oxidase activation. Biochemistry 2001;40:10007-13.
22. Zhang B, Gao Y, Moon SY, Zhang Y, Zheng Y. Oligomerization of Rac1 GTPase mediated by the carboxyl-terminal polybasic domain. J Biol Chem 2001;276:8958-67.
23. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
24. Di Poi N, Faure J, Grizot S, Molnar G, Pick E, Dagher MC. Mechanism of NADPH oxidase activation by the Rac/Rho-GDI complex Biochemistry 2001;40:10014-22.
25. Tu S, Cerione RA, Cdc42 is a substrate for caspases and influences Fas-induced apoptosis. J Biol Chem 2001;276:19656-63.
26. Wan J, Wang J, Cheng H, et al. Proteomic analysis of apoptosis initiation induced by all-trans retinoic acid in human acute promyelocytic leukemia cells. Electrophoresis 2001;22:3026-37.
27. Kovarova H, Hajduch M, Korinkova G, et al. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. Electrophoresis 2000;21:3757-64.
28. Kim R, Tanabe K, Uchida Y, Emi M, Inoue H, Toge T. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 2002;50:343-52.
29. Pervaiz S, Cao J, Chao OS, Chin YY, Clement MV. Activation of the RacGTPase inhibits apoptosis in human tumor cells. Oncogene 2001;20:6263-8.
30. Joneson T, Bar-Sagi D. Suppression of Ras-induced apoptosis by the Rac GTPase. Mol Cell Biol 1999;19:5892-901.
31. Abo A, Pick E, Hall A, Totty N, Teahan CG, Segal AW. Activation of the NADPH oxidase involves the small GTF-binding protein p21rac1. Nature 1991;353:668-70.
32. Bromberg Y, Shani E, Joseph G, Gorzalczany Y, Sperling O, Pick E. The GDP-bound form of the small G protein Rac1 p21 is a potent activator of the superoxide-forming NADPH oxidase of macrophages. J Biol Chem 1994;269:7055-8.
33. Lin Q, Fuji RN, Yang VV, Cerione RA. RhoGDI is required for Cdc42-mediated cellular transformation. Curr Biol 2003;13:1469-79.
34. Arozarena I, Matallanas D, Crespo P. Maintenance of CDC42 GDP-bound state by Rho-GDI inhibits MAP kinase activation by the exchange factor Ras-GRF, evidence for Ras-GRF function being inhibited by Cdc42-GDP but unaffected by CDC42-GTP. J Biol Chem 2001;276:21878-84.
35. Gandhi PN, Gibson RM, Tong X, et al. An activating mutant of Rac1 that fails to interact with Rho GDP-dissociation inhibitor stimulates membrane ruffling in mammalian cells. Biochem J 2004;378:409-19.